Alliance Pharma plc
APH
Delayed London Stock Exchange - 11/21 05:35:14 pm
59GBp
-0.21%
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Manufactures, develops, markets and distributes pharmaceutical products

Alliance Pharma Plc operates as a pharmaceutical company.

It manufactures, develops, markets and distributes pharmaceutical products.

Alliance's principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products.

The company portfolio includes brand building businesses focused on Dermatology, Oncology and Nutrition.

The company was founded by John Dawson in 1996 and is headquartered in Chippenham, the United Kingdom.

Number of employees : 143 persons.
Sales per Businesses
20152016
GBP
(in Million)
%GBP
(in Million)
%
Pharmaceuticals48.34100%97.49100%
Sales per Regions
20152016
GBP
(in Million)
%GBP
(in Million)
%
United Kingdom39.4481.6%49.4150.7%
Rest of the World5.6611.7%19.0819.6%
Ireland3.246.7%--
Rest of Europe--29.0129.8%
Shareholders
- John Dawson11.9%
- Thomas Theodore Casdagli11.7%
- Fidelity Management & Research Co.9.34%
- Slater Investments Ltd.7.51%
- Artemis Investment Management LLP7.24%
- GVQ Investment Management Ltd.5.05%
Managers
- CEO, Director & Head-Investor Relations :
    John Dawson
- Chairman :
    Andrew Smith
- Chief Scientific & Operations Officer :
    Stephen Kidner
- Chief Financial Officer, Director & IR Contact :
    Andrew Franklin
- Non-Executive Director :
    Thomas Casdagli
- Executive Director & Deputy CEO :
    Peter Butterfield
- Independent Non-Executive Director :
    David John Cook
- Independent Non-Executive Director :
    Nigel Clifford
- Secretary :
    Robin Bellhouse
- Director-Business Development :
    Dan Thomas
Company contact information
Alliance Pharma Plc
Avonbridge House
Bath Road
Chippenham, Wiltshire SN15 2BB

Phone : +44.1249.466966
Fax : +44.1249.466977
Web : www.alliancepharma.co.uk
Overall rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision